Status:
COMPLETED
Adult Asthmatics and Acid Reflux
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy and safety of Nexium in the treatment of subjects with persistent asthma believed to have acid reflux as a contributory factor to control of their a...
Eligibility Criteria
Inclusion
- Clinical diagnosis of asthma
- Forced Expiratory Volume and Peak Expiratory Flow as defined by the protocol
- Daily use of inhaled GCS and/or leukotriene pathway modifier for greater than 3 months.
- Severe heartburn 3 days/week during the run-in period.
Exclusion
- Subjects with a history of 3 sinus infections treated with antibiotics in the year prior to Visit 1.
- Any other significant disease or pathology judged to be clinically significant by the investigator
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2004
Estimated Enrollment :
1400 Patients enrolled
Trial Details
Trial ID
NCT00628953
Start Date
October 1 2002
End Date
April 1 2004
Last Update
March 13 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.